Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

Leukemia

Volumn 23, Issue 3, 2009, Pages 477-485

  Remsing Rix, L L ^a   Rix, U ^a   Colinge, J ^a   Hantschel, O ^a   Bennett, K L ^a   Stranzl, T ^a   Muller A ^a   Baumgartner, C ^b   Valent, P ^b   Augustin, M ^c   Till, J H ^c   Superti Furga, G ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Millipore UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ENZYME;

ARTICLE; CELL LYSATE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEOMICS;

EID: 62549166213     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.334     Document Type: Article

References (35)

1. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109: 2171-2181.
2. Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1-30.
3. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006; 354: 2594-2596.
4. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389-7395.
5. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542-2551.
6. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
7. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: The new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007; 6: 834-848.
8. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-11322.
9. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F et al SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008; 7: 1185-1194.
10. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008; 111: 2329-2338.
11. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007; 25: 1035-1044.
12. Fabian MA, Biggs III WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-336.
13. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008; 49: 615-619.
14. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non-kinase targets. Blood 2007; 110: 4055-4063.
15. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L et al. AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Res 2008; 68: 1905-1915.
16. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 2007; 104: 13283-13288.
17. Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Heinonen JE, Berglof A et al. Bruton's tyrosine kinase: Cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203: 200-215.
18. Si J, Collins SJ. Activated Ca2+/calmodulin-dependent protein kinase ligamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res 2008; 68: 3733-3742.
19. Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 1987; 47: 1731-1739.
20. Thaimattam R, Daga PR, Banerjee R, Iqbal J. 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem 2005; 13: 4704-4712.
21. van der Horst EH, Degenhardt YY, Strelow A, Slavin A, Chinn L, Orf J et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA 2005; 102: 15901-15906.
22. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL et al Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci USA 2007; 104: 8438-8443.
23. Howlin J, Rosenkvist J, Andersson T. TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells. Breast Cancer Res 2008; 10: R36.
24. Chu S, Holtz M, Gupta M, Bhatia R. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103: 3167-3174.
25. Ling P, Lu TJ, Yuan CJ, Lai MD. Biosignaling of mammalian Ste20-25 related kinases. Cell Signal 2008; 20: 1237-1247.
26. Pombo CM, Force T, Kyriakis J, Nogueira E, Fidalgo M, Zalvide J. The GCK II and III subfamilies of the STE20 group kinases. Front Biosci 2007; 12: 850-859.
27. Kruttgen A, Schneider I, Weis J. The dark side of the NGF family: neurotrophins in neoplasias. Brain Pathol 2006; 16: 304-310.
28. Gribble SM, Roberts I, Grace C, Andrews KM, Green AR, Nacheva EP. Cytogenetics of the chronic myeloid leukemia-derived cell line K562: karyotype clarification by multicolor fluorescence in situ hybridization, comparative genomic hybridization, and locus-specific fluorescence in situ hybridization. Cancer Genet Cytogenet 2000; 118: 1-8.
29. Guo JQ, Lin H, Kantarjian H, Talpaz M, Champlin R, Andreeff M et al Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002; 16: 2447-2453.
30. Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, Martinelli G, Baccarani M, Fischer T et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph+ ALL. ASH Ann Meeting Abstr 2007; 473.
31. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008; 14: 2895-2899.
32. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
33. Voisset E, Lopez S, Dubreuil P, De Sepulveda P. The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood 2007; 110: 2593-2599.
34. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531-2541.
35. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003; 63: 375-381.